Clin Asst Prof Wang Lian Chek Michael

Michael is a Radiation Oncologist with a particular interest in Uro-oncology, Gastrointestinal cancers and Proton Beam Therapy. Qualified as a Radiation Oncologist for over 22 years, Michael was appointed the Head of Department and subsequently Chair of the Division of Radiation Oncology, National Cancer Centre Singapore (NCCS) in 2020. On the professional front, he was a past-Chair of the Chapter of Radiation Oncologists, College of Radiologists Singapore and a former President of the Singapore Radiological Society (SRS). After obtaining his medical degree at the National University of Singapore in 1993, he went on to complete training in Clinical Oncology at the Middlesex Hospital, UCLH in 2002. This was followed by a HMDP Fellowship in Gastrointestinal Radiation Oncology at the Peter MacCallum Cancer Centre in 2006 and a UICC ICRETT Fellowship in Tomotherapy at Yonsei Cancer Centre in 2010.

As the Lead Program Director of the NCCS Proton Therapy Program since 2016, Michael has been responsible for the project management, training and clinical services planning of the PBT facility in NCCS. For PBT accreditation, he underwent training at the prestigious Samsung Cancer Center and the University of Hokkaido Proton Therapy Center. NCCS’ proton facility treated its first patient in June 2023 and has successfully ramped up clinical operations since. Michael is currently contributing to particle therapy community as the Vice-Chair of the Proton Therapy Cooperative Group – Asia Oceania (PTCOG-AO).

Michael’s aspiration is to lead Radiation Oncology NCCS to greater heights; to provide the latest treatment technologies for all patients, and drive the development and utility of other forms of particle therapy, for the treatment of cancers.

• FRCR (Clinical Oncology), Royal College of Radiologists (2003) 
• Graduate Diploma, Healthcare Management and Leadership, Singapore Management University (2010) 
• MBBS, National University of Singapore (1993)

• Chair, Division of Radiation Oncology, NCCS 
• Chair, Clinical Privileging and Credentialing Committee, NCCS 
• Member, NCCS Research Committee 
• Member, Radiation Oncology Residency Advisory Committee 
• Member, Radiation Oncology and Therapy Advisory Committee 
• Member, National Environment Agency Advisory Committee
•  Vice-Chair, Particle Therapy Cooperative Group Asia Oceania

• SingHealth Quality Awards – Star Award 2024

• Radiation-Induced Hemorrhagic Cystitis in Prostate Cancer Survivors: The Hidden Toll. Gatsinga R, Lim BJH, Kumar N, Tan JGG, Li Y, Wang MLC, Tan TWK, Tuan JKL, Tan YG, Chen K, Yuen JSP. Me-dicina (Kaunas). 2024 Oct 24;60(11):1746 
• A meta-analysis comparing efficacy and safety between proton beam therapy versus carbon ion radiother-apy. Jang JY, Kim K, Chen MF, Akimoto T, Wang MLC, Kim MJ, Kim K, Lee TH, Yoo GS, Park HC. Cancer Med. 2024 Feb;13(3):e7023 
• Transcriptomic analyses of localized prostate cancers of East Asian and North American men reveal race-specific luminal-basal and microenvironmental differences. Chua MLK, Hakansson AK, Ong EHW, Hong BH, Miao JJ, Sim AYL, Tan JSH, Tan KM, Lee GCJ, Low KP, Tuan JKL, Tan TWK, Wang MLC, Yeong JPS, Tan MCS, Lee LS, Kanesvaran R, Zhao X, Ho J, Spratt DE, Schaeffer EM, Tay KJ, Liu Y, Davicioni E, Khor LY. Cancer Commun (Lond). 2023 Oct;43(10):1164-1168 
• Cardiovascular toxicities of androgen deprivation therapy in Asian men with localized prostate cancer after curative radiotherapy: a registry-based observational study. Li Y, Ong WS, Shwe MTT, Yit NLF, Quek SZH, Pang EPP, Looi WS, Nei WL, Wang MLC, Chua MLK, Tan TWK, Chua ET, Ng CT, Tuan JKL. Cardiooncology. 2022 Mar 14;8(1):4. 
• Efficacy, toxicity, and quality-of-life outcomes of ultrahypofractionated radiotherapy in patients with local-ized prostate cancer: A single-arm phase 2 trial from Asia. Tan JSH, Teh JYH, Tan LLY, Tan SXF, Li YQ, Tan TWK, Wang MLC, Kanesvaran R, Ong EHW, Tay KJ, Lee LS, Tu-an JKL, Tan DYH, Chua MLK. Asia Pac J Clin Oncol. 2022 Oct;18(5):e346-e355. 
• Predicting outcomes for locally advanced rectal cancer treated with neoadjuvant chemoradiation with CT-based radiomics. Wang F, Tan BF, Poh SS, Siow TR, Lim FLWT, Yip CSP, Wang MLC, Nei W, Tan HQ. Sci Rep. 2022 Apr 13;12(1):6167 
• Technical considerations for positioning and placement of a transperineal ultrasound probe during prostate radiotherapy. Pang EPP, Knight K, Leung RW, Wang MLC, Chan JWS, Low GK, Seah IKL, Atan MAB, Chai JYH, Ng GC, Yang TC, Tuan JKL. J Med Radiat Sci. 2021 Jun; 68(2):196-202 
• Early Outcomes of a National Cancer Center's Strategy Against COVID-19 Executed Through a Disease Out-break Response Taskforce. Kwek JW, Chan JJ, Kanesvaran R, Wang MLC, Neo PSH, Chia CS, Tham CK, Chew LST, Tan HK, Yap SP, Dent RA, Hwang WYK, Lim ST. JCO Oncol Pract. 2021 Mar; 17(3):e343-e354 
• Investigation of a 22-gene genomic classifier (GC) for risk stratification and molecular subtyping in an Asian prostate cancer (PCa) cohort. Yee WLS, Woo WY, Sim A, Low KP, Meng A, Tan JSH, Tuan J, Tan TWK, Wang MLC, Tay KJ, Cheng C, Yeong JPS, Lee LS, Kanesvaran R, Tan MCS, Davicioni E, Khor LY, Chua MLK. J Clin Oncol. 2021 Mar; 39(6_Suppl):249 
• The implementation of an advanced practice radiation therapy (APRT) program in Singapore. Wong SMM, Sin SY, Lim LH, Nurul Tassha BMA, Lin J, Melissa K, Koh WY, Ho F, Quah DSC, Sommat K, Tuan JKL, Wong FY, Ng WL, Yeo RMC, Soong YL, Wang MLC. Tech Innov Patient Support Radiat Oncol. 2021 Mar; 17:63-70 
• Chemoradiation-induced changes in systemic inflammatory markers and their prognostic significance in oesophageal squamous cell carcinoma. Khin NS, Tan SH, Wang ML, Siow TR, Lim FL, Wang FQ, Ng MC, Lam JY, Yip C. Brit J Radiol. 2021 Jun; 94(1122):20200314 
• Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the Nation-al Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma. Chew XH, Sultana R, Mathew EN, Ng DCE, Lo RHG, Toh HC, Tai D, Choo SP, Goh BKP, Yan SX, Loke KSH, Thang SP, Gogna A, Venkatanarasimha NK, Tong AKT, Moe FNN, Chua JSS, Ang RWT, Ong AD, Ng AWY, Ho-ang MTQ, Too CW, Tng CH, Chang WY, Kee W, Chan JHM, Irani F, leong S, Lim KH, Wang MLC, Chow PKH. Liver Cancer. 2021 Jun; 10(3):224-239